Close Menu


The company had initially said it expected a price range of between $8 and $10, but the IPO will now go off at $6 per share.

The company said that a UK court today agreed to sanction its plan to float in the US, conditional upon the execution of the Underwriter Agreement by Osmetech and the underwriters before 7 a.m. BST, Friday.

Osmetech expects to raise proceeds of around $35 million from the offering, which part of a plan to set up its headquarters in the US.

A majority of Osmetech's shareholders voted in favor of the plan to float in the US, change the firm's name, and relocate its headquarters to California.

The British molecular diagnostics firm intends to raise around $40 million in a US IPO and will be based in the US as a wholly-owned subsidiary of GenMark Diagnostics.

BG has filed for an IPO in the US, a few years after withdrawing an effort to float on the Euronext Amsterdam Exchange.

Med BioGene said that the purpose of the rights plan is to provide sufficient time to its board and shareholders to assess any unsolicited takeover bids.

The Canadian firm, which already floats on the Toronto Stock Exchange, is gearing up for the launch of its LungExpress Dx product in the US.

RBM, which held around $3 million in cash and cash equivalents as of the end of September, is developing a psychiatric diagnostics panel.

The proceeds will support commercialization of the company's gene expression-based assay for early-stage non-small-cell lung cancer.


The Wall Street Journal reports on the struggle to meet the demand for rapid COVID-19 testing.

The Newsroom reports New Zealand is using genomics to trace the origins of its new coronavirus outbreak.

In Nature this week: researchers in Canada sequence the genome of the black mustard plant Brassica nigra, and more.

According to Bloomberg, Moderna has a $1.5 billion vaccine deal with the US to provide 100 million doses.